Literature DB >> 8113410

Role of interleukin-10 in T helper cell dysfunction in asymptomatic individuals infected with the human immunodeficiency virus.

M Clerici1, T A Wynn, J A Berzofsky, S P Blatt, C W Hendrix, A Sher, R L Coffman, G M Shearer.   

Abstract

The loss of T helper cell (TH) function in asymptomatic HIV type 1-infected individuals occurs before the decline in CD4+ T cells. At least part of the loss in TH function results from changes in immunoregulatory cytokine profiles. To investigate the role of IL-10 in such dysregulation, we tested whether: (a) expression of IL-10-specific mRNA would be upregulated in PBMC from asymptomatic, HIV-infected (HIV+) individuals; (b) PBMC from these same individuals would produce increased levels of IL-10 when stimulated in vitro with phytohemagglutinin; and (c) defective antigen-specific TH function could be restored by anti-IL-10 antibody. We observed that IL-10-specific mRNA was marginally upregulated, and increased levels of IL-10 were produced by PBMC from HIV+ individuals compared with PBMC from uninfected individuals. Those individuals whose TH function was more severely compromised produced higher levels of IL-10. Additionally, defective antigen-specific TH function in vitro could be reversed by anti-IL-10 antibody, including the response to HIV envelope synthetic peptides. Furthermore, the antigen-specific TH responses of HIV-uninfected PBMC could be reduced with IL-10, a process reversed by anti-IL-10. These results confirm that the early loss of TH function in HIV+ individuals is due at least in part to cytokine-induced immune dysregulation, and support the hypothesis of a switch from a predominant type 1 state to a predominant type 2 condition in HIV infection.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8113410      PMCID: PMC293925          DOI: 10.1172/JCI117031

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  43 in total

1.  Human B-cell interleukin-10: B-cell lines derived from patients with acquired immunodeficiency syndrome and Burkitt's lymphoma constitutively secrete large quantities of interleukin-10.

Authors:  D Benjamin; T J Knobloch; M A Dayton
Journal:  Blood       Date:  1992-09-01       Impact factor: 22.113

2.  Changes in interleukin-2 and interleukin-4 production in asymptomatic, human immunodeficiency virus-seropositive individuals.

Authors:  M Clerici; F T Hakim; D J Venzon; S Blatt; C W Hendrix; T A Wynn; G M Shearer
Journal:  J Clin Invest       Date:  1993-03       Impact factor: 14.808

3.  Estimating prognosis in HIV-1 infection.

Authors:  J P Phair
Journal:  Ann Intern Med       Date:  1993-05-01       Impact factor: 25.391

4.  A factor from CD8 cells of human immunodeficiency virus-infected patients suppresses HLA self-restricted T helper cell responses.

Authors:  M Clerici; E Roilides; C S Via; P A Pizzo; G M Shearer
Journal:  Proc Natl Acad Sci U S A       Date:  1992-09-15       Impact factor: 11.205

5.  Reconstitution of long-term T helper cell function after zidovudine therapy in human immunodeficiency virus-infected patients.

Authors:  M Clerici; A L Landay; H A Kessler; J P Phair; D J Venzon; C W Hendrix; D R Lucey; G M Shearer
Journal:  J Infect Dis       Date:  1992-10       Impact factor: 5.226

6.  CD4+ lymphocytes are an incomplete surrogate marker for clinical progression in persons with asymptomatic HIV infection taking zidovudine.

Authors:  S Choi; S W Lagakos; R T Schooley; P A Volberding
Journal:  Ann Intern Med       Date:  1993-05-01       Impact factor: 25.391

7.  Reciprocal regulatory effects of IFN-gamma and IL-4 on the in vitro development of human Th1 and Th2 clones.

Authors:  E Maggi; P Parronchi; R Manetti; C Simonelli; M P Piccinni; F S Rugiu; M De Carli; M Ricci; S Romagnani
Journal:  J Immunol       Date:  1992-04-01       Impact factor: 5.422

8.  Changes in T-helper cell function in human immunodeficiency virus-infected children during didanosine therapy as a measure of antiretroviral activity.

Authors:  M Clerici; E Roilides; K M Butler; L DePalma; D Venzon; G M Shearer; P A Pizzo
Journal:  Blood       Date:  1992-11-01       Impact factor: 22.113

9.  Human IL-10 is produced by both type 1 helper (Th1) and type 2 helper (Th2) T cell clones and inhibits their antigen-specific proliferation and cytokine production.

Authors:  G Del Prete; M De Carli; F Almerigogna; M G Giudizi; R Biagiotti; S Romagnani
Journal:  J Immunol       Date:  1993-01-15       Impact factor: 5.422

10.  Macrophage deactivation by interleukin 10.

Authors:  C Bogdan; Y Vodovotz; C Nathan
Journal:  J Exp Med       Date:  1991-12-01       Impact factor: 14.307

View more
  110 in total

1.  99th Dahlem conference on infection, inflammation and chronic inflammatory disorders: viruses, autoimmunity and immunoregulation.

Authors:  C M Filippi; M G von Herrath
Journal:  Clin Exp Immunol       Date:  2010-04       Impact factor: 4.330

Review 2.  Translating insights from persistent LCMV infection into anti-HIV immunity.

Authors:  Elizabeth B Wilson; David G Brooks
Journal:  Immunol Res       Date:  2010-12       Impact factor: 2.829

3.  Cell-intrinsic IL-27 and gp130 cytokine receptor signaling regulates virus-specific CD4⁺ T cell responses and viral control during chronic infection.

Authors:  James A Harker; Aleksandr Dolgoter; Elina I Zuniga
Journal:  Immunity       Date:  2013-08-29       Impact factor: 31.745

4.  IL10 and PD-1 Cooperate to Limit the Activity of Tumor-Specific CD8+ T Cells.

Authors:  Zhaojun Sun; Julien Fourcade; Ornella Pagliano; Joe-Marc Chauvin; Cindy Sander; John M Kirkwood; Hassane M Zarour
Journal:  Cancer Res       Date:  2015-02-26       Impact factor: 12.701

5.  IL-10 in HIV infection: increasing serum IL-10 levels with disease progression--down-regulatory effect of potent anti-retroviral therapy.

Authors:  E Stylianou; P Aukrust; D Kvale; F Müller; S S Frøland
Journal:  Clin Exp Immunol       Date:  1999-04       Impact factor: 4.330

6.  Low interleukin-10 production is associated with diabetes in HIV-infected patients undergoing antiviral therapy.

Authors:  Daria Trabattoni; Monica Schenal; Miriam Cesari; Eleonora Castelletti; Michela Pacei; Billi Goldberg; Andrea Gori; Mario Clerici
Journal:  Med Microbiol Immunol       Date:  2006-01-26       Impact factor: 3.402

Review 7.  Animal models for viral infection and cell exhaustion.

Authors:  Colleen S McGary; Guido Silvestri; Mirko Paiardini
Journal:  Curr Opin HIV AIDS       Date:  2014-09       Impact factor: 4.283

8.  Effects of TH1 and TH2 cytokines on CD8+ cell response against human immunodeficiency virus: implications for long-term survival.

Authors:  E Barker; C E Mackewicz; J A Levy
Journal:  Proc Natl Acad Sci U S A       Date:  1995-11-21       Impact factor: 11.205

9.  Blockade of chronic type I interferon signaling to control persistent LCMV infection.

Authors:  Elizabeth B Wilson; Douglas H Yamada; Heidi Elsaesser; Jonathan Herskovitz; Jane Deng; Genhong Cheng; Bruce J Aronow; Christopher L Karp; David G Brooks
Journal:  Science       Date:  2013-04-12       Impact factor: 47.728

10.  Cell-intrinsic transforming growth factor-beta signaling mediates virus-specific CD8+ T cell deletion and viral persistence in vivo.

Authors:  Roberto Tinoco; Victor Alcalde; Yating Yang; Karsten Sauer; Elina I Zuniga
Journal:  Immunity       Date:  2009-07-17       Impact factor: 31.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.